作者: Giulia Calenda , Ines Frank , Géraldine Arrode-Brusés , Amarendra Pegu , Keyun Wang
DOI: 10.1101/365551
关键词:
摘要: Passive transfer of VRC01 protects macaques from vaginal SHIV infection after a single high-dose challenge. Protection against repeated rectal challenges decreases with decreased antibody levels weeks infusion. has not been tested; however, it is expected to decrease similarly. Infusion simianized anti-α4β7 mAb (Rh-α4β7) just prior to, and during exposures SIVmac251 partially protected SIV minimized the decline CD4+ T cells. To investigate impact combining Rh-α4β7 on infection, 3 groups were treated suboptimal dosing alone or in combination control antibodies initiation weekly high dose (1000TCID50) SHIVAD8-EO. The Rh-α4β7-VRC01 significantly delayed SHIVAD8-EO infection. Following VRC01-Rh-α4β7-treated maintained higher cell counts compared other exhibited lower SIV-DNA loads controls. Interestingly, had less IL-17 producing cells blood gut tissue acute phase responses V2-loop envelope groups. amounts altered anti-viral immune loss. Further exploration effect bNAbs SIV/HIV warranted may lead novel preventive therapeutic strategies.